He Ya, Xu Hanshi, Liang Liuqin, Zhan Zhongping, Yang Xiuyan, Yu Xueqing, Ye Yujin, Sun Lin
First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Arthritis Rheum. 2008 Nov;58(11):3366-76. doi: 10.1002/art.23986.
There is increasing evidence that the RhoA signaling pathway may play a critical role in the inflammatory response. This study was undertaken to examine the effects of RhoA and its downstream effector Rho kinase (ROK) in synovial inflammation in rheumatoid arthritis (RA).
RhoA activity was assessed by pull-down assay. Fasudil and Y27632, both specific inhibitors of ROK, were used to examine the role of ROK in inflammatory responses in vivo and in vitro. Nuclear translocation of NF-kappaB was measured by confocal fluorescence microscopy, and DNA binding activity was assessed with a sensitive multiwell colorimetric assay. Enzyme-linked immunosorbent assay was used to detect cytokine production.
Increased activation of RhoA was found in inflamed synovial membrane cells isolated from patients with RA and from rats with collagen-induced arthritis (CIA). Intraperitoneal administration of fasudil in rats with CIA significantly reduced synovial inflammation and ROK activity. In vitro, treatment with fasudil or Y27632 decreased production of tumor necrosis factor alpha (TNFalpha), interleukin-1beta (IL-1beta), and IL-6 by synovial membrane cells, peripheral blood mononuclear cells, and fibroblast-like synoviocytes from patients with active RA. Inhibition of ROK by specific inhibitors or ROK small interfering RNA suppressed lipopolysaccharide- or TNFalpha-induced NF-kappaB nuclear translocation, DNA binding activity, luciferase reporter gene expression, and IkappaBalpha degradation.
The results of this study provide new evidence that blockade of ROK inhibits activation of NF-kappaB and production of proinflammatory cytokines, suggesting a critical role of ROK in the synovial inflammation of RA. Specific inhibition of ROK may be a novel therapeutic approach in RA.
越来越多的证据表明,RhoA信号通路可能在炎症反应中起关键作用。本研究旨在探讨RhoA及其下游效应物Rho激酶(ROK)在类风湿关节炎(RA)滑膜炎症中的作用。
通过下拉试验评估RhoA活性。使用ROK的特异性抑制剂法舒地尔和Y27632来研究ROK在体内和体外炎症反应中的作用。通过共聚焦荧光显微镜测量NF-κB的核转位,并用灵敏的多孔比色法评估DNA结合活性。采用酶联免疫吸附测定法检测细胞因子的产生。
在从RA患者和胶原诱导性关节炎(CIA)大鼠分离的炎症滑膜细胞中发现RhoA的激活增加。对CIA大鼠腹腔注射法舒地尔可显著减轻滑膜炎症和ROK活性。在体外,用 法舒地尔或Y27632处理可降低活动性RA患者的滑膜细胞、外周血单核细胞和成纤维样滑膜细胞产生肿瘤坏死因子α(TNFα)、白细胞介素-1β(IL-1β)和IL-6的水平。用特异性抑制剂或ROK小干扰RNA抑制ROK可抑制脂多糖或TNFα诱导的NF-κB核转位、DNA结合活性、荧光素酶报告基因表达和IκBα降解。
本研究结果提供了新的证据,即阻断ROK可抑制NF-κB的激活和促炎细胞因子的产生,表明ROK在RA滑膜炎症中起关键作用。特异性抑制ROK可能是RA的一种新的治疗方法。